Literature DB >> 15583138

Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.

Denise M Crooks1, Gustavo Pacheco-Rodriguez, Rosamma M DeCastro, J Philip McCoy, Ji-an Wang, Fumiyuki Kumaki, Thomas Darling, Joel Moss.   

Abstract

Lymphangioleiomyomatosis (LAM) is a multisystem disorder of women, characterized by cystic degeneration of the lungs, renal angiomyolipomas (AML), and lymphatic abnormalities. LAM lesions result from the proliferation of benign-appearing, smooth muscle-like LAM cells, which are characterized by loss of heterozygosity (LOH) of one of the tuberous sclerosis complex (TSC) genes. LAM cells are believed to migrate among the involved organs. Because of the apparently metastatic behavior of LAM, we tried to isolate LAM cells from body fluids. A cell fraction separated by density gradient centrifugation from blood had TSC2 LOH in 33 of 60 (55%) LAM patients. Cells with TSC2 LOH were also found in urine from 11 of 14 (79%) patients with AML and in chylous fluid from 1 of 3 (33%) patients. Identification of LAM cells with TSC2 LOH in body fluids was not correlated with severity of lung disease or extrapulmonary involvement and was found in one patient after double lung transplantation. These studies are compatible with a multisite origin for LAM cells. They establish the existence of disseminated, potentially metastatic LAM cells through a relatively simple, noninvasive procedure that should be valuable for molecular and genetic studies of somatic mutations in LAM and perhaps other metastatic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583138      PMCID: PMC536045          DOI: 10.1073/pnas.0407971101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

Review 1.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.

Authors:  S Johnson
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis.

Authors:  K Matsui; K Takeda; Z X Yu; W D Travis; J Moss; V J Ferrans
Journal:  Arch Pathol Lab Med       Date:  2000-02       Impact factor: 5.534

3.  Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma.

Authors:  G M Hampton; A A Larson; R N Baergen; R L Sommers; S Kern; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis.

Authors:  S C Chu; K Horiba; J Usuki; N A Avila; C C Chen; W D Travis; V J Ferrans; J Moss
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

5.  Epitopes immunologically related to glycophorin A on human malignant and non-malignant cells in culture.

Authors:  A L Barsoum; M S Czuczman; V P Bhavanandan; E A Davidson
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

6.  Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.

Authors:  Y Matsumoto; K Horiba; J Usuki; S C Chu; V J Ferrans; J Moss
Journal:  Am J Respir Cell Mol Biol       Date:  1999-09       Impact factor: 6.914

7.  Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

Authors:  T A Smolarek; L L Wessner; F X McCormack; J C Mylet; A G Menon; E P Henske
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

8.  Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage.

Authors:  N Brouwenstijn; E H Slager; A B Bakker; M W Schreurs; C W Van der Spek; G J Adema; P I Schrier; C G Figdor
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis.

Authors:  F Bonetti; P L Chiodera; M Pea; G Martignoni; F Bosi; G Zamboni; G M Mariuzzi
Journal:  Am J Surg Pathol       Date:  1993-11       Impact factor: 6.394

Review 10.  Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers.

Authors:  T Nakahata; N Okumura
Journal:  Leuk Lymphoma       Date:  1994-05
View more
  80 in total

1.  A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis.

Authors:  Hannah Peavy; Dorothy Gail; James Kiley; Susan Shurin
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

Review 2.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

3.  Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Authors:  Yoshihiko Ikeda; Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Souheil El-Chemaly; Bernadette R Gochuico; Rose M May; Olanda M Hathaway; Shaowei Li; Ji-an Wang; Thomas N Darling; Mario Stylianou; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

4.  Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Poay N Lim; Daniel Noonan; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-30       Impact factor: 6.914

5.  Lymphangioleiomyomatosis--presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets.

Authors:  Henrik Watz; Knut Engels; Siegfried Loeschke; Michael Amthor; Detlef Kirsten; Helgo Magnussen
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

Review 6.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

7.  Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

8.  "Universal" vitrification of cells by ultra-fast cooling.

Authors:  Yun Seok Heo; Sunitha Nagrath; Alessandra L Moore; Mahnaz Zeinali; Daniel Irimia; Shannon L Stott; Thomas L Toth; Mehmet Toner
Journal:  Technology (Singap World Sci)       Date:  2015-03

9.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

10.  Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

Authors:  Chenggang Li; Xiaobo Zhou; Yang Sun; Erik Zhang; John D Mancini; Andrey Parkhitko; Tasha A Morrison; Edwin K Silverman; Elizabeth P Henske; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.